Timothy Joseph Yeatman

age ~66

from Dunnellon, FL

Get Report

Also known as:

Connected to:

Timothy Yeatman Phones & Addresses

Methods Of Classifying Human Subjects With Regard To Cancer Prognosis
view source
US Patent:

20140031251, Jan 30, 2014
Filed:

Nov 2, 2011
Appl. No.:

13/883478
Inventors:

Timothy Yeatman - Greenville SC, US
Andrey Loboda - Philadelphia PA, US
Hongyue Dai - Chestnut Hill MA, US
Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C12Q 1/68
US Classification:

506 9
Abstract:

In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting cancer patient prognosis based on whether the cancer is classified as having a high or low EMT Signature Score.

Method Of Predicting Non-Response To First Line Chemotherapy
view source
US Patent:

20150160223, Jun 11, 2015
Filed:

Dec 5, 2014
Appl. No.:

14/561950
Inventors:

Timothy J. Yeatman - Spartanburg SC, US
Deepak Agrawal - Tampa FL, US
Adil Daud - Hillsborough CA, US
Assignee:

UNIVERSITY OF SOUTH FLORIDA - Tampa FL
H.Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL
International Classification:

G01N 33/574
G01N 27/447
C12Q 1/68
Abstract:

The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor.